BIO: Venture capital trends toward rare disease medicines
This article was originally published in Scrip
Executive Summary
Drugs to treat rare diseases have been a popular area for venture capitalists to put their investment over the past decade, according to a new report from the Biotechnology Industry Organization (BIO).